Form 4 holding
EVP Finance CFO
REGENERON PHARMACEUTICALS, INC.
- Security class
- Common Stock
- Shares / value
- 23,693
- Estimated value
- $22,665,908
- Report date
- 02 Feb 2024
- Price
- $956.65
- Ownership
- Direct
Robert E. Landry
Insider Reports History
- Reporting-owner location
- Tarrytown, NY
- Latest reporting-owner signature
- /s/ John O. Faurescu, attorney-in-fact for Mr. Landry
- Transaction source note
- Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.
Identity
Names, identifiers, and filing context for this profile.
1 identity field
SEC source record
Original filing metadata and source links for verification.
1 source field
Source evidence
Original filing metadata and source links for verification.
1 source field
Reported holdings for Robert E. Landry
Form 4 holding
Director
CYTOKINETICS INC
- Security class
- Common Stock
- Shares / value
- 10,184
- Estimated value
- $671,227
- Report date
- 27 May 2026
- Price
- $65.91
- Ownership
- Direct
Form 4 holding
EVP Finance CFO
REGENERON PHARMACEUTICALS, INC.
- Security class
- Common Stock
- Shares / value
- 270
- Estimated value
- $252,372
- Report date
- 02 Feb 2024
- Price
- $934.71
- Ownership
- By 401(k) Plan
Form 4 holding
EVP Finance CFO
REGENERON PHARMACEUTICALS, INC.
- Security class
- Non-Qualified Stock Option (right to buy)
- Shares / value
- 11,787
- Estimated value
- Report date
- 02 Feb 2024
- Price
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Director
Zymeworks Inc.
- Security class
- Stock Option (Right to Buy)
- Shares / value
- 11,500
- Estimated value
- Report date
- 12 Jan 2026
- Price
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Director
Zymeworks Inc.
- Security class
- Restricted Stock Unit
- Shares / value
- 7,700
- Estimated value
- Report date
- 12 Jan 2026
- Price
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Director
CYTOKINETICS INC
- Security class
- Non-Qualified Stock Option (Right to Buy)
- Shares / value
- 4,301
- Estimated value
- Report date
- 27 May 2026
- Price
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Director
Zymeworks Inc.
- Security class
- No securities are beneficially owned
- Shares / value
- 0
- Estimated value
- Report date
- 10 Aug 2025
- Price
- Ownership
- Direct
Insider Reports Filed by Robert E. Landry
4
CYTK
CYTOKINETICS INC
- Report period
- 27 May 2026
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 27 May 2026, 19:09
- Role
- Director
- Next action
- Open filing details
4
ZYME
Zymeworks Inc.
- Report period
- 12 Jan 2026
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 12 Jan 2026, 20:56
- Role
- Director
- Next action
- Open filing details
4
ZYME
Zymeworks Inc.
- Report period
- 11 Aug 2025
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 12 Aug 2025, 20:30
- Role
- Director
- Next action
- Open filing details
3
ZYME
Zymeworks Inc.
- Report period
- 10 Aug 2025
- Transactions
- 0
- Transaction value
- $0
- Accepted by SEC
- 12 Aug 2025, 20:00
- Role
- Director
- Next action
- Open filing details
4
CYTK
CYTOKINETICS INC
- Report period
- 14 May 2025
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 14 May 2025, 19:27
- Role
- Director
- Next action
- Open filing details
4
CYTK
CYTOKINETICS INC
- Report period
- 10 Feb 2025
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 11 Feb 2025, 08:26
- Role
- Director
- Next action
- Open filing details
3
CYTK
CYTOKINETICS INC
- Report period
- 10 Feb 2025
- Transactions
- 0
- Transaction value
- $0
- Accepted by SEC
- 11 Feb 2025, 08:18
- Role
- Director
- Next action
- Open filing details
4
REGN
REGENERON PHARMACEUTICALS, INC.
- Report period
- 02 Feb 2024
- Transactions
- 3
- Transaction value
- -$117,227
- Accepted by SEC
- 06 Feb 2024, 16:08
- Role
- EVP Finance CFO
- Next action
- Open filing details
4
REGN
REGENERON PHARMACEUTICALS, INC.
- Report period
- 31 Jan 2024
- Transactions
- 3
- Transaction value
- -$117,272
- Accepted by SEC
- 02 Feb 2024, 16:02
- Role
- EVP Finance CFO
- Next action
- Open filing details
4
REGN
REGENERON PHARMACEUTICALS, INC.
- Report period
- 23 Jan 2024
- Transactions
- 6
- Transaction value
- -$464,512
- Accepted by SEC
- 25 Jan 2024, 16:17
- Role
- EVP Finance CFO
- Next action
- Open filing details
4
REGN
REGENERON PHARMACEUTICALS, INC.
- Report period
- 17 Jan 2024
- Transactions
- 3
- Transaction value
- -$140,558
- Accepted by SEC
- 18 Jan 2024, 16:02
- Role
- EVP Finance CFO
- Next action
- Open filing details
4
REGN
REGENERON PHARMACEUTICALS, INC.
- Report period
- 12 Jan 2024
- Transactions
- 3
- Transaction value
- -$224,022
- Accepted by SEC
- 17 Jan 2024, 16:03
- Role
- EVP Finance CFO
- Next action
- Open filing details
4
REGN
REGENERON PHARMACEUTICALS, INC.
- Report period
- 04 Jan 2024
- Transactions
- 3
- Transaction value
- -$124,141
- Accepted by SEC
- 08 Jan 2024, 16:02
- Role
- EVP Finance CFO
- Next action
- Open filing details
4
REGN
REGENERON PHARMACEUTICALS, INC.
- Report period
- 02 Jan 2024
- Transactions
- 6
- Transaction value
- -$338,439
- Accepted by SEC
- 04 Jan 2024, 16:19
- Role
- EVP Finance CFO
- Next action
- Open filing details
4
REGN
REGENERON PHARMACEUTICALS, INC.
- Report period
- 27 Dec 2023
- Transactions
- 6
- Transaction value
- -$407,916
- Accepted by SEC
- 29 Dec 2023, 16:05
- Role
- EVP Finance CFO
- Next action
- Open filing details
4
REGN
REGENERON PHARMACEUTICALS, INC.
- Report period
- 12 Dec 2023
- Transactions
- 4
- Transaction value
- -$5,717,506
- Accepted by SEC
- 14 Dec 2023, 16:08
- Role
- EVP Finance CFO
- Next action
- Open filing details
4
REGN
REGENERON PHARMACEUTICALS, INC.
- Report period
- 08 Dec 2023
- Transactions
- 3
- Transaction value
- -$3,573,573
- Accepted by SEC
- 12 Dec 2023, 16:01
- Role
- EVP Finance CFO
- Next action
- Open filing details
4
REGN
REGENERON PHARMACEUTICALS, INC.
- Report period
- 23 Aug 2023
- Transactions
- 1
- Transaction value
- -$188,212
- Accepted by SEC
- 25 Aug 2023, 16:02
- Role
- EVP Finance CFO
- Next action
- Open filing details
4
REGN
REGENERON PHARMACEUTICALS, INC.
- Report period
- 27 Mar 2023
- Transactions
- 22
- Transaction value
- -$1,841,829
- Accepted by SEC
- 29 Mar 2023, 16:07
- Role
- EVP Finance CFO
- Next action
- Open filing details
4
REGN
REGENERON PHARMACEUTICALS, INC.
- Report period
- 03 Feb 2023
- Transactions
- 18
- Transaction value
- -$1,753,048
- Accepted by SEC
- 07 Feb 2023, 15:09
- Role
- EVP Finance CFO
- Next action
- Open filing details
4
REGN
REGENERON PHARMACEUTICALS, INC.
- Report period
- 16 Dec 2022
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 20 Dec 2022, 15:07
- Role
- EVP Finance CFO
- Next action
- Open filing details
4
REGN
REGENERON PHARMACEUTICALS, INC.
- Report period
- 08 Dec 2022
- Transactions
- 4
- Transaction value
- -$962,523
- Accepted by SEC
- 12 Dec 2022, 15:34
- Role
- EVP Finance CFO
- Next action
- Open filing details
4
REGN
REGENERON PHARMACEUTICALS, INC.
- Report period
- 01 Dec 2022
- Transactions
- 6
- Transaction value
- -$943,825
- Accepted by SEC
- 02 Dec 2022, 15:05
- Role
- EVP Finance CFO
- Next action
- Open filing details
4
REGN
REGENERON PHARMACEUTICALS, INC.
- Report period
- 31 Oct 2022
- Transactions
- 13
- Transaction value
- -$741,929
- Accepted by SEC
- 02 Nov 2022, 16:04
- Role
- EVP Finance CFO
- Next action
- Open filing details
4
REGN
REGENERON PHARMACEUTICALS, INC.
- Report period
- 14 Oct 2022
- Transactions
- 4
- Transaction value
- -$541,258
- Accepted by SEC
- 18 Oct 2022, 16:06
- Role
- EVP Finance CFO
- Next action
- Open filing details
4
REGN
REGENERON PHARMACEUTICALS, INC.
- Report period
- 07 Apr 2022
- Transactions
- 28
- Transaction value
- -$3,276,534
- Accepted by SEC
- 11 Apr 2022, 18:01
- Role
- EVP Finance CFO
- Next action
- Open filing details
4
REGN
REGENERON PHARMACEUTICALS, INC.
- Report period
- 31 Mar 2022
- Transactions
- 5
- Transaction value
- -$450,357
- Accepted by SEC
- 01 Apr 2022, 16:07
- Role
- EVP Finance CFO
- Next action
- Open filing details
4
REGN
REGENERON PHARMACEUTICALS, INC.
- Report period
- 28 Mar 2022
- Transactions
- 29
- Transaction value
- -$3,758,253
- Accepted by SEC
- 30 Mar 2022, 16:42
- Role
- EVP Finance CFO
- Next action
- Open filing details
4
REGN
REGENERON PHARMACEUTICALS, INC.
- Report period
- 21 Mar 2022
- Transactions
- 4
- Transaction value
- -$270,821
- Accepted by SEC
- 23 Mar 2022, 16:02
- Role
- EVP Finance CFO
- Next action
- Open filing details
4
REGN
REGENERON PHARMACEUTICALS, INC.
- Report period
- 16 Mar 2022
- Transactions
- 5
- Transaction value
- -$315,832
- Accepted by SEC
- 18 Mar 2022, 16:08
- Role
- EVP Finance CFO
- Next action
- Open filing details
4
REGN
REGENERON PHARMACEUTICALS, INC.
- Report period
- 10 Dec 2021
- Transactions
- 5
- Transaction value
- -$625,837
- Accepted by SEC
- 14 Dec 2021, 15:03
- Role
- EVP Finance CFO
- Next action
- Open filing details
4
REGN
REGENERON PHARMACEUTICALS, INC.
- Report period
- 08 Dec 2021
- Transactions
- 21
- Transaction value
- -$1,101,437
- Accepted by SEC
- 10 Dec 2021, 16:37
- Role
- EVP Finance CFO
- Next action
- Open filing details
4
REGN
REGENERON PHARMACEUTICALS, INC.
- Report period
- 16 Nov 2021
- Transactions
- 4
- Transaction value
- -$941,470
- Accepted by SEC
- 18 Nov 2021, 15:23
- Role
- EVP Finance CFO
- Next action
- Open filing details
4
REGN
REGENERON PHARMACEUTICALS, INC.
- Report period
- 31 Aug 2021
- Transactions
- 3
- Transaction value
- -$63,333
- Accepted by SEC
- 01 Sep 2021, 16:05
- Role
- EVP Finance CFO
- Next action
- Open filing details
4
REGN
REGENERON PHARMACEUTICALS, INC.
- Report period
- 06 Aug 2021
- Transactions
- 22
- Transaction value
- -$1,159,116
- Accepted by SEC
- 10 Aug 2021, 17:55
- Role
- EVP Finance CFO
- Next action
- Open filing details